Dr. Clay Siegall is the CEO and president of the Bothell, Washington based biotechnology company Seattle Genetics. The company is at the forefront of cancer research and has provided physicians all over the world with effective treatments to help them improve life for cancer patients. Dr. Siegall has a BS in Zoology from the University of Maryland and earned a PhD in genetics from George Washington University. A scientist by training, Dr. Siegall founded Seattle Genetics in 1998 as a company focused on using rigorous research, scientific innovation and visionary drug development practices.
Dr. Siegall does more than just help to guide Seattle Genetics in the development of antibody drug conjugates to be used to treat cancer, he is also the company’s chief fundraiser. He has led capital-raising activities from public and private sources that have secured over $675 million. Dr. Siegall has also generated over $300 million for the company through multiple strategic licenses he has arranged for the company’s proprietary ADC technology. Dr. Siegall has license agreements with AbbVie, Genentech, Pfizer and GlaxoSmithKline. Seattle Genetics also has 20 ADCs currently in clinical development internal and collaborator programs that use the company’s technology.
As part of his commitment to cancer research Dr. Siegall shares his time and expertise with numerous companies developing new treatment methods. Since 2006 he’s been director of the board of Alder Biopharmaceuticals, Mirna Therapeutics and Ultragenyx Pharmaceutical. Through this role he has helped those companies with fund raising and work on targeted cancer therapies. All of that is part of the legacy of this visionary cancer researcher. He has also worked with Bristol-Myers Squibb Pharmaceutical Research Institute, the National Institutes of Health as well as the National Cancer Institute.
Dr. Siegall has received many awards and accolades for his work in cancer research and treatment. In 2013 he was voted Alumnus of the Year for Computer, Math and Natural Sciences by the University of Maryland. In 2012 he was selected as Entrepreneur of the Year Pacific Northwest by Ernst & Young. Dr. Siegall’s writings have appeared in over 70 publications. He also holds 15 patents.